Contributions
Abstract: P903
Type: Poster
Abstract Category: Clinical aspects of MS - Clinical assessment tools
Background: In the BECOME study, 75 multiple sclerosis (61 with relapsing remitting and 14 with CIS) were treated for up to 26 consecutive months. The clinical outcomes of the study have been reported.The Comparative Brain Imaging (CoBI) software developed by Philips Healthcare aids in visual detection of brain parenchymal changes.
Goals:The goal of this study is to compare the efficacy of magnetic resonance (MR) fat-suppressed T1 weighted and fluid-attenuated inversion recovery (FLAIR) subtracted images in detecting brain atrophy in multiple sclerosis (MS) patients by using the CoBI software.
Methods: This retrospective study included 10 patients with MS. The patients underwent MRI brain at 3-Tesla at the start of the study and at 12 and 24 months (2 patients did not follow up at 24 months). The CoBI software (Intellispace Discovery, Philips Healthcare, Best, The Netherlands) was used to support visual qualitative assessment of brain atrophy between two axial images. The software was used to create digitally subtracted images comparing the follow-up scans with the initial scan displayed on a color scale. A total of 20 slices at and cranial to the foramen of Monro were evaluated for both the FLAIR and T1 sequences comparing each follow up scan to the patient"s original scan. The mean difference between the number of slices demonstrating atrophy on FLAIR versus T1 sequences was analyzed using Wilcoxon signed rank test. The severity of each patient"s global brain atrophy on the 24-month subtracted images for both the FLAIR and T1 was graded on a scale of zero to three. The mean difference of slices showing atrophic changes was correlated to the radiologist"s global atrophy score for both sequences using the Spearman correlation.
Results: Subtracted FLAIR images identified more atrophy than T1 at both the 12 and 24-month time intervals (respective p-values of .005 and .030). There was 52% more atrophy detected at 12 and 41% more atrophy detected at 24 months with FLAIR. The correlation analysis showed the mean difference in atrophy detection was correlated with the global atrophy score on both FLAIR (r = 0.90) and T1 (r = 0.82) sequences.
Conclusion: In this population of 10 patients with RR MS, FLAIR showed to be more efficacious in detecting brain atrophy utilizing CoBI software than fat-suppressed T1 images.
Disclosure: Mojgan Hojjati, research fellowship sponsored by Philips Health Care.
Tyler Richards no disclosure
Curtis Tatsuoka, no disclosure
Frank Thiele, Philips Health Care research scientist
Leo Wolansky, no disclosure
The BECOME study was supported by a grant from Bayer Healthcare Pharmaceuticals, but was the intellectual property of the investigators.
Abstract: P903
Type: Poster
Abstract Category: Clinical aspects of MS - Clinical assessment tools
Background: In the BECOME study, 75 multiple sclerosis (61 with relapsing remitting and 14 with CIS) were treated for up to 26 consecutive months. The clinical outcomes of the study have been reported.The Comparative Brain Imaging (CoBI) software developed by Philips Healthcare aids in visual detection of brain parenchymal changes.
Goals:The goal of this study is to compare the efficacy of magnetic resonance (MR) fat-suppressed T1 weighted and fluid-attenuated inversion recovery (FLAIR) subtracted images in detecting brain atrophy in multiple sclerosis (MS) patients by using the CoBI software.
Methods: This retrospective study included 10 patients with MS. The patients underwent MRI brain at 3-Tesla at the start of the study and at 12 and 24 months (2 patients did not follow up at 24 months). The CoBI software (Intellispace Discovery, Philips Healthcare, Best, The Netherlands) was used to support visual qualitative assessment of brain atrophy between two axial images. The software was used to create digitally subtracted images comparing the follow-up scans with the initial scan displayed on a color scale. A total of 20 slices at and cranial to the foramen of Monro were evaluated for both the FLAIR and T1 sequences comparing each follow up scan to the patient"s original scan. The mean difference between the number of slices demonstrating atrophy on FLAIR versus T1 sequences was analyzed using Wilcoxon signed rank test. The severity of each patient"s global brain atrophy on the 24-month subtracted images for both the FLAIR and T1 was graded on a scale of zero to three. The mean difference of slices showing atrophic changes was correlated to the radiologist"s global atrophy score for both sequences using the Spearman correlation.
Results: Subtracted FLAIR images identified more atrophy than T1 at both the 12 and 24-month time intervals (respective p-values of .005 and .030). There was 52% more atrophy detected at 12 and 41% more atrophy detected at 24 months with FLAIR. The correlation analysis showed the mean difference in atrophy detection was correlated with the global atrophy score on both FLAIR (r = 0.90) and T1 (r = 0.82) sequences.
Conclusion: In this population of 10 patients with RR MS, FLAIR showed to be more efficacious in detecting brain atrophy utilizing CoBI software than fat-suppressed T1 images.
Disclosure: Mojgan Hojjati, research fellowship sponsored by Philips Health Care.
Tyler Richards no disclosure
Curtis Tatsuoka, no disclosure
Frank Thiele, Philips Health Care research scientist
Leo Wolansky, no disclosure
The BECOME study was supported by a grant from Bayer Healthcare Pharmaceuticals, but was the intellectual property of the investigators.